Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients

NCT00819741 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00819741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2009
Completion date
November 30, 2009
Enrollment
433 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2